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Abstract
Detecting persistent minimal residual disease (MRD) allows the identification of patients with an increased risk of
relapse and death. In this study, we have evaluated MRD 3 months after transplantation in 106 myeloma patients using
a commercial next-generation sequencing (NGS) strategy (LymphoTrack®), and compared the results with next-
generation flow (NGF, EuroFlow). The use of different marrow pulls and the need of concentrating samples for NGS
biased the applicability for MRD evaluation and favored NGF. Despite that, correlation between NGS and NGF was high
(R2= 0.905). The 3-year progression-free survival (PFS) rates by NGS and NGF were longer for undetectable vs. positive
patients (NGS: 88.7% vs. 56.6%; NGF: 91.4% vs. 50%; p < 0.001 for both comparisons), which resulted in a 3-year overall
survival (OS) advantage (NGS: 96.2% vs. 77.3%; NGF: 96.6% vs. 74.9%, p < 0.01 for both comparisons). In the Cox
regression model, NGS and NGF negativity had similar results but favoring the latter in PFS (HR: 0.20, 95% CI: 0.09–0.45,
p < 0.001) and OS (HR: 0.21, 95% CI: 0.06–0.75, p= 0.02). All these results reinforce the role of MRD detection by
different strategies in patient prognosis and highlight the use of MRD as an endpoint for multiple myeloma treatment.
Introduction
Multiple myeloma (MM) is a B-cell malignancy where
plasma cells arise from a single clone accumulated in the
bone marrow1, and usually produce monoclonal immu-
noglobulins (M-protein or monoclonal component). New
agents such as proteasome inhibitors and immunomodula-
tory drugs2,3, together with autologous stem cell
transplantation (ASCT)4 have increased the proportion of
patients achieving complete response (CR) in this disease,
which has been translated into better progression-free sur-
vival (PFS) and overall survival (OS) rates during the last 10
years5–7. This improvement led to the definition of new
response categories (i.e. stringent complete response, sCR)8,
but even myeloma patients with such good responses still
relapse due to the presence of residual tumor cells in the
bone marrow (i.e. minimal residual disease, MRD)9–11 that
remain undetectable by conventional serological and mor-
phological methods. New methods are capable of detecting
MRD with a higher prediction ability, since negative patients
had longer survival rates compared to positive patients12–14,
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even when only patients in CR are considered15. Accord-
ingly, the International Myeloma Working Group (IMWG)
developed new criteria to define MRD negative responses,
characterized by the absence of clonal malignant plasma
cells in patients with suspected CR, assessed with a sensi-
tivity of at least 10−5—one malignant cell per hundred
thousand normal cells16; therefore, only very sensitive and
reliable methods can be applied to detect MRD.
Nowadays, MRD in MM can be studied using two dif-
ferent approaches: immunophenotypic (multiparametric
flow cytometry, MFC)17 and molecular techniques (next-
generation sequencing —NGS—, digital PCR)18. Imaging
tools (PET-CT, MRI) can add some extra information in
terms of prognostic evaluation19, however, standardized
procedures to perform MRD assessment in myeloma have
only been developed for MFC20 and NGS21. Despite the
added value for MRD assessment, next-generation stra-
tegies are currently used only in a few centers and usually
limited to the context of clinical trials.
MFC allows the identification and quantification of
abnormal plasma cells based on an aberrant protein-
marker expression profile displayed by myeloma cells.
Recently, the EuroFlow consortium has developed a two-
tube, eight-color flow assay that allows the simultaneous
analysis of up to 10 million cells (next-generation flow,
NGF)22; NGF has been already approved by the IMWG as
a reference method to detect and define immunopheno-
typic CRs in MM16. NGF reaches a sensitivity of 2 × 10−6,
overcoming previous flow protocols (10−4–10−5), but it is
highly dependent on the precise identification of the
pathologic immunophenotype, requiring a high level of
expertise; in addition, the quality of the sample must be
high and should be promptly processed23.
Molecular methods use the clonal immunoglobulin gene
rearrangement as target for the detection of MRD levels.
Quantitative PCR uses allele-specific oligonucleotides
targeting the junction region of the immunoglobulin
genes; it has been extensively used as the molecular gold-
standard approach to detect MRD levels in lymphoid
malignancies24,25. Nonetheless, it is a labor-intensive
technique, requiring the construction of a standard curve
for every single patient, and its applicability accounts only
for 40–75% of myeloma patients24,25. By contrast, NGS
strategies have been rapidly introduced in the clinical
setting, especially for myeloma. However, the only strategy
approved by the IMWG16 and cleared by the FDA —
Adaptive’s clonoSEQ®— is not commercially available,
and its cost makes it unaffordable for most centers.
We aimed at validating the potential applicability and
usefulness of a new NGS methodology for the diagnosis
and MRD detection in MM patients. To that end, we have
evaluated a commercial NGS panel, LymphoTrack®, in a
cohort of 106 myeloma patients, and compared the results
with NGF.
Materials and methods
Patient and sample selection
Patient selection was based on the following criteria:
(i) newly diagnosed MM, transplant-candidate patients
included in the Spanish GEM2012 clinical trial7, whose
clonotypic rearrangements were previously identified,
(ii) NGF evaluation performed at diagnosis and follow-
up per protocol, and (iii) enough amount of gDNA
available for MRD studies. Bone marrow samples from
eligible MM patients were collected at day 100 follow-
ing transplantation: two independent pulls were
obtained and subsequently processed to perform flow
and molecular studies.
Patients with t(4;14), t(14;16), or del17p by FISH were
grouped together in a high-risk cytogenetic subgroup
according to the IMWG criteria26. The revised interna-
tional staging system (R-ISS)27 was also applied to stratify
patients according to the ISS stage, serum LDH, and
cytogenetics. The study was conducted in accordance
with Declaration of Helsinki principles, was approved by
the Committee of the University Hospital of Salamanca,
and written informed consent was required and obtained
from each patient prior to their inclusion.
DNA extraction and quantification
gDNA was isolated from bone marrow aspirates of
newly diagnosed MM patients using the automated DNA
Purification kit Maxwell® (Promega, Madison, WI, USA).
gDNA quality was first assessed using NanoDrop2000
(ThermoFisher, Waltham, MA, USA). Samples were
quantified using Qubit 2.0 and the dsDNA BR assay
(ThermoFisher, Waltham, MA, USA).
To improve the quality of follow-up samples, those with
insufficient DNA concentration for MRD purposes (i.e.
those with <100 ng/µl) were ethanol-precipitated. To do
this, 1/10 volume sodium acetate, as well as twice the
sample volume of 100% ethanol (stored at −20 °C) were
added to the samples and incubated overnight at −20 °C.
Afterwards, samples were centrifuged at 17,900 × g and
4 °C for 10min. The nucleic acid pellet was then washed
with 500 µl ethanol (70%) and centrifuged again at
17,900 × g and 4 °C for 5 min. Finally, the pellet was dried
and rehydrated in ≈12 µl of water, and quantified using
the Qubit dsDNA BR assay.
Gene amplification and sequencing
The LymphoTrack® IGH panel (Invivoscribe Tech-
nologies, San Diego, CA, USA) was used for the analysis
of MRD samples to detect previously characterized clo-
notypic rearrangements of the immunoglobulin heavy
chain loci (IGH). Clonal rearrangements were first
determined in matched baseline samples by PCR ampli-
fication and Sanger sequencing using the BIOMED-2
primers as previously described28.
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Briefly, this commercial NGS strategy uses primers
targeting the immunoglobulin framework regions in order
to amplify V(D)J rearrangements. In one-step PCR (Fig.
S1) amplicons are generated and one-side indexed,
allowing the simultaneous sequencing of up to 24 samples
in a single run. Whenever possible, ≥650 ng of DNA were
used to reach a sensitivity level of at least 10−5 (assuming
6.5 pg of DNA per cell, input for NGS would be at least
100,000 cells). In addition, DNA from one clonal, well-
characterized B cell line was added in each reaction as a
control spike-in (corresponding to 100 cells), to allow the
absolute quantification of tumor plasma cells.
After a purification step with Agentcourt AMPure XP
microbeads (Beckman Coulter Inc., Brea, CA, USA) and
70% ethanol, and purity and quantity assessment using
the TapeStation 4200 (Agilent, Santa Clara, CA, USA) and
KAPA library quantification kit (KAPA Biosystems, Bos-
ton, MA, USA) or Qubit 2.0, respectively, amplicon
libraries of 12–20 pM were prepared. These libraries were
later sequenced in a MiSeq platform (Illumina, San Diego,
CA, USA) using v3 reagent kits and 2 × 251 sequencing
cycles, aiming at one million reads per sample.
Sequence analysis and MRD evaluation
Resulting FastQ files were processed using the Lym-
phoTrackAnalysis® software and the LymphoTrack®
MRD Data Analysis tool 1.1.0 (Invivoscribe Technologies)
to retrieve sequences from virtually every clonal B cell of
the samples. This allowed the identification of residual
tumor cells, if present, by tracking their clonotypic IGH
complementarity-determining region 3 (CDR3) that had
previously been characterized. The software performs a
calculation considering the number of spike-in cells used
for each reaction, as well as tumor and spike-in read
counts. Sequencing results were considered invalid when
<20,000 total reads were obtained. A sample was con-
sidered positive for MRD assessment when at least two
identical clonotypic reads were detected; conversely, a
sample was considered negative (undetectable) for MRD
when criteria for positivity were not met. Vidjil (Uni-
versity of Lille) and Arrest/Interrogate (EuroNGS) tools
were also used to analyze FastQ files from MRD
sequencing.
In order to make comparisons, patients were eventually
classified into different groups according to the MRD
status (MRD-positive and MRD-negative), the MRD level
(MRD-negative, MRD-positive below 10−5, MRD-positive
between 10−5 and 10−4, and MRD-positive higher than
10−4), the conventional response (VGPR/PR and sCR/
CR), and the cytogenetic risk (high- and standard-risk).
MFC studies
Follow-up samples were processed within 24 h after
collection. Analysis was carried out using the recently
developed NGF methodology (Table S1), following the
EuroFlow guidelines, as described elsewere20,22. Events
from two eight-color tubes (per sample) were merged
using the merge function of the INFINICYT™
v2.0 software (Cytognos S.L. Salamanca, Spain). A sample
was considered positive when at least 20 aberrant plasma
cells were detected. Hemodilution of bone marrow sam-
ples for NGF evaluation was assessed through the iden-
tification of a significant decrease in non-plasma cell
populations: mast cells (CD117hi), erythroblasts (CD45−/
sideward-scatterlo) and B-cell precursors (CD19+/
CD38hi/CD45lo). The complete analysis of NGF perfor-
mance for the GEM2012 trial has already been
published28.
Statistical analysis
Patients’ characteristics were analyzed with the SPSS
23.0 software (IBM, Armonk, NY, USA) using Fisher’s
exact test for discrete variables and the Mann–Whitney
test for continuous variables. Bland–Altman plots were
used to test the potential agreement between methods.
The Kaplan–Meier method and the log-rank test were
used to plot and compare PFS and OS curves. Cox
regression was used to perform univariate and multi-
variate analyses. By Landmark analysis, only those patients
who had not progressed or died on day 100 post ASCT
were evaluated. PFS was defined as the time from MRD
assessment to the last follow-up visit, disease progression
or death by any cause. OS was defined as the time from
MRD assessment to the last follow-up visit or patient’s
decease by any cause. All reported p values were obtained
by a two-sided exact method, at the conventional 5%
significance level (p < 0.05).
Results
Patient characteristics
One hundred and six (106) patients met the inclusion
criteria. Clinical variables of our cohort are described in
Table S2. Median age at diagnosis was 59 years. Male to
female proportion was 58/42. Patients with high-risk
cytogenetics represented 22.5% of the present series [n=
23/102, one of them with t(4;14) plus del17p]. The R-ISS
stages I, II, and III represented 25.2%, 59.2%, and 15.5% of
patients, respectively. After a median follow-up of
39.5 months from MRD assessment (interquartile range:
33.8–46.2 months), 31 patients had relapsed (29.2%) and
16 had died (15.1%), two of them without progression, due
to infections.
At the corresponding MRD evaluation time point, the
overall response rate was 96.2%: 32.1% of patients
achieved sCR, 23.6% CR, 34.0% very good partial response
(VGPR) and 6.6% partial response (PR). Only four patients
(3.8%) had stable/progressive disease (SD/PD). Three-year
PFS and OS rates were 72.5% and 86.7%, respectively.
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Comparison of NGS and NGF performance
Sample quality and ethanol precipitation were the main
variables affecting NGS applicability for MRD analysis.
Because of that, the minimum number of cell equivalents
to reach a virtual sensitivity of 10−5 could only be used in
95 (89.6%) cases (Table 1). According to the inclusion
criteria, NGF was successfully used for the evaluation of
the entire series, with a significantly higher number of
cells required to perform the studies at the aimed sensi-
tivity threshold. The analysis of precursor B cells, ery-
throblasts, and mast cells did not reveal significant
hemodilution of any sample evaluated by flow cytometry.
MRD-negativity was achieved by 53 (50.0%) and 58
(54.7%) patients by NGS and NGF, respectively. Further
stratification of patients according to the MRD level is
shown in Table 2.
As it is shown in Fig. 1A, we found a good correlation
between methods (r= 0.951; R2= 0.905), with 15 dis-
cordant cases (5 NGF+/NGS−; 10 NGF−/NGS+). It is
worth mentioning that the majority of NGS-only MRD-
positive cases (7/10) presented values below 10−5, while
this situation was found in two out of five NGF-only
MRD-positive cases. Bland–Altman analysis demon-
strated an excellent level of agreement between NGS and
NGF (Fig. 1B).
Characteristics of patients with undetectable MRD who
had disease progression
With a median follow-up of 39.5 months, disease pro-
gression was confirmed in 31 cases: 23 double-positive
patients, three discordant cases (two positive cases by
NGF, one positive case by NGS), and five patients with
double-negative MRD (by both NGS and NGF).
Table S3 lists the characteristics of the five patients who
had undetectable MRD and progressed: all of them
achieved CR at the time of MRD assessment, had low/
intermediate ISS status and LDH was normal. Of note,
two of these patients had extramedullary disease (one
already present at diagnosis), while another one relapsed
after more than 3 years in sustained MRD negativity, one
year following their treatment suspension. The other two
patients had conventional disease progressions
~36 months after transplantation.
Undetectable MRD was clinically significant by NGS and
NGF
Negative patients showed a significantly better 3-year
PFS rate than positive patients (p < 0.001), either basing
on NGS or NGF results (88.7% vs. 56.6%; 91.4% vs. 50%,
Fig. 2A and B, respectively, p < 0.001). Three-year OS
rates were very high for all subgroups: considering NGS,
3-year OS rates of negative and positive patients were
96.2% and 77.3%, respectively (Fig. 3A; p < 0.01). Con-
sidering NGF, 3-year OS rates of negative and positive
patients were 96.6% and 74.9%, respectively (Fig. 3B; p <
0.01). There were no statistical differences in PFS between
double-negative and discordant cases (36-month PFS:
91.7% and 80%, respectively, p= 0.55, Fig. S2), while both
subgroups had significantly better PFS rates than double-
negative cases (median PFS: 34.2 months, p < 0.05 for
both comparisons).
Moreover, survival rates progressively increased from
patients with high-positive MRD to patients with unde-
tectable residual disease (Fig. S3): by NGS, 36-month PFS
rates of ≥10−4, 10−5− 10−4, <10−5 and negative groups
were 55%, 52.9%, 62.5%, and 88.7%, respectively (p < 0.01).
By NGF, they were 38.9%, 47.6%, 77.8%, and 91.4%,
respectively (p < 0.001). OS rates of these subsets followed
the same trend.
Table 1 Cell input for NGS- and NGF-based MRD studies.
Input cells NGS NGF
<105 10.4%a 0%
105− 2 × 105 32.1% 0%








Median sensitivity 10−5 2 × 10−6
Cell input range 3542–726,264 1,548,175–15,000,000
Each cell shows the frequency of samples that were analyzed at different cell
input levels. The number of cell equivalents used for NGS was calculated based
on Qubit2.0 quantification, assuming 6.5 pg DNA/cell.
aOne sample was sequenced with a cell input below 10,000 cells.
Table 2 MRD stratification for next-generation flow and
next-generation sequencing.
MRD level Current study GEM20127
NGS NGF NGF
Negative 53 (50.0%) 58 (54.7%) 173 (54.6%)
<10−5 16 (15.1%)a 9 (8.5%) 18 (5.7%)a
≥10−5 and <10−4 17 (16.0%) 21 (19.8%) 65 (20.5%)
≥10−4 20 (18.9%) 18 (17.0%) 61 (19.2%)
Total 106 106 317
MRD results, obtained using NGS or NGF, were compared for the 106 patients in
our cohort. Results obtained in the GEM2012 Spanish trial,7 (intent-to-treat
population) were used as a reference. Absolute numbers and percentage (in
parenthesis) for each MRD category are shown in each cell.
MRD minimal residual disease, NGF next-generation flow, NGS next-generation
sequencing.
aFisher’s exact test showed statistical differences in the proportions of each
subgroup (two-sided p= 0.004).
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MRD overcomes response-to-treatment and cytogenetics
as a predictive factor
As in prior reports, we correlated the MRD status with
different clinical variables such as heavy and light chains
usage, ISS, R-ISS, cytogenetics, and conventional
response. We only detected a significant association
between achieving CR/sCR and MRD negativity (Fig. S4).
Thus, by NGS we observed that 71.2% of patients in CR/
Fig. 1 Comparison of MRD results. A Linear regression. Ninety-one out of one hundred and six samples (91/106, 85.8%) were concordant between
techniques. Only 15/106 cases (14.2%) were discordant. B Bland–Altman plot comparing NGS and NGF performance (n= 43, only double-positive
cases were evaluated). Mean MRD values of methods (shown in the x-axis) were calculated. Differences in log10 scale for each case (y-axis) were
calculated as follows: log10(higher MRD value/lower MRD value). Then, negative values were assigned to those cases where the MRD level estimated
by NGS > NGF, while positive values were assigned to those case where the MRD estimated by NGS < NGF. Normal distribution of the differences was
first assessed (Kolmogorov–Smirnov’s p > 0.05, n= 42 degrees of freedom). The Student’s T-test (t= 0.33, SD= 1.15; n= 42 degrees of freedom) was
used to calculate the average of differences (bias), where a positive value indicates a general overestimation made by NGF, and a negative value
indicates an overestimation made by NGS. Upper and lower limits of agreement were calculated as the bias ± 1.96 multiplied by the standard
deviation of the differences. 95% confidence interval limits for mean and agreement limits are represented as gray shades. Overall, the bias was non-
significant (mean: 0.06, p > 0.05), which means that the average estimation made by NGF is 100.06 or 1.15 times higher than that made by NGS.
Differences between methods were homogenously distributed across the range of MRD levels (x-axis), with the limits of agreement approximately
set in ±102 and only 3/43 cases (7%) outside the acceptable range.
Fig. 2 Kaplan–Meier curves comparing progression-free survival of MRD-positive and MRD-negative subsets. A Progression-free survival of
NGS-based results. B Progression-free survival of NGF-based results. Time was calculated from the time of MRD assessment, 3 months after
transplantation. Negative patients are represented in black; positive patients are represented in red. Patients at risk are shown at each time point
below plots; events are represented between parentheses. Median PFS of positive patients was 46.7 and 34.2 months for NGS and NGF, respectively.
Median PFS was not achieved by negative patients. MRD minimal residual disease, NGF next-generation flow, NGS next-generation sequencing.
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sCR were MRD negative, while only 23.3% of patients in
VGPR/PR achieved MRD negativity (p < 0.0001); when
NGF data were used, 81.4% of patients in CR/sCR were
MRD-negative versus only 20.9% of patients in VGPR/PR
(p < 0.0001). No differences were observed in the pro-
portion of each group when both techniques were com-
pared (p > 0.05).
A significant relationship between negative MRD and
longer PFS was observed irrespective to the response (Fig.
S5) when patients achieving at least VGPR were con-
sidered (n= 95). Remarkably, MRD-negative patients
achieving VGPR showed comparable 3-year PFS rates to
those achieving CR or sCR; this result was similar either
considering NGS (VGPR: 88.9%, CR/sCR: 88·1%; p > 0.05)
or NGF data (VGPR: 100%, CR/sCR: 89.6%; p > 0.05). On
the other hand, MRD-positive patients had inferior out-
comes, with no differences observed between responses.
Then, we stratified patients (n= 102) into four groups
considering the MRD status (positive or negative) and
cytogenetics (high-risk or standard-risk). MRD-negative
patients showed excellent 3-year PFS rates independently
of their cytogenetic status (Fig. S6), while the outcome of
MRD-positive patients was significantly determined by
their cytogenetic profile: 3-year PFS rates were prolonged
for standard-risk patients (67.1% by NGS, 61.8% by NGF),
while for high-risk patients it was 28.6% by NGS and
15.4% by NGF (median PFS: 14.5 months by NGS and
12.8 months by NGF, p < 0.01 compared to the other
groups). For OS (Fig. S7), all MRD-negative patients
showed comparable 3-year survival rates to those patients
showing MRD positivity but no high-risk cytogenetic
alteration (OS rates >90% for all categories, p > 0.05 for all
paired comparisons); conversely, survival rates of high-
risk, MRD-positive patients were significantly lower than
the other subgroups (median OS: 21.7 months for NGS
and NGF, p < 0.01 for all paired comparisons). Interest-
ingly, 55% (6/11) of t(4;14) patients achieved MRD
negativity, while only 12.5% (1/8) of patients with del17p
were MRD negative.
Univariate and multivariate analyses
When the univariate analyses for PFS and OS were
performed (Table 3), the MRD status detected by NGS
and NGF were amongst the most statistically significant
variables associated with the outcome: hazard ratios (HRs)
for PFS according to the MRD status after transplantation
were 0.20 for NGF (95% CI: 0.09–0.44, p < 0.001) and 0.29
for NGS (95% CI: 0.14–0·63, p= 0.002); HRs for OS were
0.18 for NGF (95% CI: 0.05–0.62, p= 0.007) and 0.21 for
NGS (95% CI: 0.06–0.75, p= 0.02).
In the multivariate Cox regression models (Table 4),
MRD negativity achieved by NGF (HR: 0.20, 95% CI:
0.09–0.45, p < 0.001) and the R-ISS I or II (HR: 0.37, 95%
CI: 0.17–0.78, p= 0.01) were associated with the lowest
risk of progression or death with independent value.
Similarly, MRD negativity achieved by NGF was sig-
nificantly associated with a decreased risk of death (HR:
0.21, 95% CI: 0.06–0.75, p= 0.02), along with the R-ISS
(HR: 0.13, 95% CI: 0.05–0.38, p < 0.001). MRD negativity
by NGS had similar results but it was removed from the
stepwise analysis because of its close association with
MRD by NGF. Nonetheless, when the analysis was done
Fig. 3 Kaplan–Meier curves comparing the overall survival of MRD-positive and MRD-negative subsets. A Overall survival of NGS-based
results. B Overall survival of NGF-based results. Time was calculated from the time of MRD assessment, 3 months after transplantation. Negative
patients are represented in black; positive patients are represented in red. Patients at risk are shown at each time point below plots; events are
represented between parentheses. Median overall survival was not achieved by positive or negative patients (3-year OS rates of NGS-positive vs. NGS-
negative patients: 77.3% vs. 96.2%; 3-year OS rates of NGF-positive vs. NGF-negative patients: 74.9% vs. 96.6%). MRD minimal residual disease, NGF
next-generation flow, NGS next-generation sequencing.
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using the 10-5 cutoff, considering only the 95 patients not
affected by preanalytical pitfalls, MRD negativity by NGF
(HR: 0.16, 95% CI: 0.07–0.37, p < 0.001) and the R-ISS
(HR: 0.30, 95% CI: 0.12–0.72, p= 0.007) were still selected
for PFS, while MRD negativity by NGS (HR: 0.15, 95% CI:
0.04–0.57, p= 0.005) and the R-ISS (HR: 0.13, 95% CI:
0.04–0.39, p < 0.001) were selected for OS, indicating a
similar potential for prediction.
Discussion
MRD evaluation has arisen as a very promising tool to
predict the outcome of hematologic patients. On this
behalf, the IMWG validated the use of this parameter to
evaluate the deepest responses to treatment, measured
either by flow or sequencing16. Moreover, the FDA has
recently cleared the use of NGS to perform MRD analyses.
However, to date only one strategy has been approved
(Adaptive’s clonoSEQ), which makes access difficult for
many centers, and raises the need to find other suitable
strategies. Here, we have evaluated and compared two
different strategies: NGF, developed by the EuroFlow
group and recommended by the IMWG, and the NGS-
based LymphoTrack® IGH panel, a commercial strategy
designed by Invivoscribe Technologies.
MRD results are highly dependent on the quality and
concentration of the samples, which is directly related to
Table 3 Univariate analysis for progression-free and overall survival.
Variable (N) Univariate analysis for PFS Univariate analysis for OS
Median survival HR [95% CI] p Median survival HR [95% CI] p
Sex
Male (61) NA 1.36 [0.68–2.78] >0.05 NA 1.01 [0.38–2.71] >0.05
Female (45) NA NA
Cytogenetic risk
High risk (23) 40.02 2.99 [1.45–6.16] 0.003 NA 6.33 [2.24–17.86] <0.001
Standard risk (79) NA NA
LDH
High (20) NA 1.73 [0.80–3.72] >0.05 NA 2.00 [0.69–5.75] >0.05
Low (86) NA NA
ISS stage
I or II (70) NA 0.63 [0.31–1.31] >0.05 NA 0.22 [0.07–0.67] <0.01
III (33) NA NA
R-ISS stage
I or II (87) NA 0.34 [0.16–0.74] 0.008 NA 0.12 [0.04–0.44] <0.001
III (16) 34.20 36.1
Conventional response
sCR/CR (59) NA 0.54 [0.27–1.08] >0.05 NA 0.36 [0.12–1.04] >0.05
VGPR/PR (43) NA NA
MRD status (NGF)
Negative (58) NA 0.20 [0.09–0.44] <0.001 NA 0.18 [0.05–0.62] 0.007
Positive (48) 34.20 NA
MRD status (NGS)
Negative (53) NA 0.29 [0.14–0.63] 0.002 NA 0.21 [0.06–0.75] 0.02
Positive (53) 46.72 NA
Cox’s proportional hazards model was used to test individual variables. The number of patients corresponding to each variable’s category is shown in parenthesis.
Hazard ratios were calculated comparing first vs. second subgroup of each variable.
CI confidence interval, CR complete response, HR hazard ratio, ISS international staging system, LDH lactate dehydrogenase, MRD minimal residual disease, NA not
achieved, NGF next-generation flow, NGS next-generation sequencing, PR partial response, R-ISS revised international staging system, sCR stringent complete
response, VGPR very good partial response.
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preanalytical conditions9–11,20. Since flow cytometry
requires an immediate experimental procedure, this is
usually taken as a disadvantage compared to NGS, whose
samples can be frozen and stored after gDNA extraction
for later analyses. On the other hand, NGS relies on the
identification of clonotypic rearrangements at diagnosis,
making that up to 10% of cases cannot be followed due to
somatic hypermutation in primer-annealing regions,
though this was not the case in this study, and once it is
characterized, CDR3 regions represent a stable and reli-
able tool for MRD evaluation29. Other major flaws of NGS
are the turnaround time, which is longer than for NGF
(5–7 days compared to 24–48 h), and the need to run a
high number of samples together. In contrast, inter-
pretation of results is usually more difficult for NGF,
requiring high expertise, while LymphoTrack’s solution is
more user-friendly and semi-automated.
In our study, the use of ethanol precipitation resulted in
suboptimal sample quantity, given that, in our experience,
up to 40% of gDNA may be lost during its processing
workflow, and the use of ethanol and sodium acetate
usually turns to an increment of contaminating sub-
stances (salts and alcohol) that could interfere with PCR
amplification. Accordingly, all the samples were optimal
for NGF studies (criteria for inclusion), while 10% of the
samples were suboptimal for NGS. If we had considered
only optimal samples for both technologies, results would
have favored NGS based on its slightly higher sensitivity
using fewer cells; this represents a major advantage over
NGF, that requires the acquisition of 10,000,000 events.
However, all studies were done on an intention-to-study
analysis, mimicking the intention-to-treat analysis that we
usually see in clinical trials.
Despite being limited by the concentration method and
the poor quality of certain samples, NGS was found to be
fairly concordant with NGF in terms of MRD detection
and quantification ability. Although we detected 15 dis-
cordant cases, only three of those patients relapsed (two
positive cases by NGF, one positive case by NGS). In
contrast, highly concordant results were observed in the
MRD evaluation of the remaining 28 relapsing patients:
23 were double-positive and only five were negative by
both methods, which could be explained by risk factors
already present at diagnosis, extramedullary relapses24, or
infiltration levels below the limit of detection.
Most discordant cases had MRD levels below 10−5, that
may be explained either by a higher sensitivity for one
method over the other, or in the case of NGS, if technical
inaccuracies due to the use of the spike in for quantifi-
cation were present (i.e. underestimation of the MRD
level). The only six discordant cases (NGS= 3; NGF= 3)
with MRD levels over 10−5 could be explained based on
differences in the sampling procedure (different tubes
from different bone marrow pulls), since sensitivity was
set in the range of 10−5−10−6 for both techniques. Only
three discordant cases relapsed, and accordingly no dif-
ferences were seen with double-negative patients in terms
of PFS, although an intermediate survival rate could be
expected in a broader population with longer follow up.
According to the standard design of clinical trials, MRD
is evaluated at several timepoints irrespective of the
response. In our study, eight patients who had achieved
VGPR as confirmed by immunofixation and electro-
phoresis had undetectable residual disease by next-
generation techniques. This finding is concordant with a
situation where tumor plasma cells had been eradicated in
the bone marrow, while the monoclonal component was
still present in the blood stream. Noteworthy, five of them
achieved ≥CR after consolidation, supporting the notion
that, in the clinical practice, MRD should be assessed
whenever patients achieve CR16,30.
Cytogenetic status still maintained its potential to
stratify patients, but only when applied to the MRD-
positive subset, a feature that has already been described
for patients treated with the combination of bortezomib,
lenalidomide, and dexamethasone31. As far as this study is
concerned, it seems that this treatment scheme could
overcome the negative prognostic impact of t(4;14) and be
able to provide MRD-negative responses. By contrast, 17p
deletion still retained its association with poor survival
rates, and was strongly correlated with MRD positivity.
Regarding the multivariate analysis, NGF retained a
more independent informative capacity for survival than
NGS because it was selected before in the multivariate






HR [95% CI] p HR [95% CI] p
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Those variables with a significant impact in the univariate analysis were
introduced in a multivariate Cox regression model to determine which ones
were predictive for survival. Hazard ratios were calculated comparing first vs.
second subgroup of each variable. Cytogenetics were included only as part of
the R-ISS score.
CI confidence interval, HR hazard ratio, MRD minimal residual disease, NGF next-
generation flow, NGS next-generation sequencing, R-ISS revised international
staging system.
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analysis and the results of the two methods were closely
associated. This result has to be interpreted with caution
because the preanalytical conditions strongly affected
NGS and could not be considered by the multivariate
analysis. Despite that, NGS provided consistent and
comparable results to NGF when only non-biased cases
were evaluated.
As Perrot et al. have recently stated14, both NGF and
NGS can reach a sensitivity of 10−6 when more cells are
used and, in this context, the most important factor is not
the technique but the ability to detect deeper levels of
MRD, avoiding false-negative results due to lower detec-
tion limits. Direct comparison of MRD quantification by
NGS and NGF in the same conditions (i.e. reaching the
same sensitivity level and using the same marrow pull)
should be performed to shed light into this issue, although
an intrinsic false-negativity risk will always exist for both
methodologies due to the patchy nature of the disease. As
it was mentioned before, samples undergoing laboratory
analysis are not the same, and a great variation can be
detected from the first marrow pull (which is usually sent
to the morphology laboratory) to the last one (which is
distributed for molecular, cytogenetic, and immunophe-
notypic studies)23,32. This could be a feasible explanation
for the 15 discordant cases in our cohort. Nonetheless,
our study demonstrates the similarity between NGS and
NGF, with analogous results to those reported in the
GEM2012 overall analysis of MRD by NGF30 but using
~10 times less cells.
In summary, our results support the use of the Lym-
phoTrack® strategy to detect and evaluate MRD in MM
patients, with excellent applicability and comparable
results to NGF. Altogether, these findings reinforce the
use of MRD assessment as an endpoint in MM clinical
trials and underline the need of standardization and
quality assessment in future studies for all MRD
approaches in MM.
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